Nexalin Technology (NXL) Liabilities and Shareholders Equity (2021 - 2026)
Nexalin Technology (NXL) posted quarterly Liabilities and Shareholders Equity of $3.7 million for Q1 2026, up 27.4% year-over-year from $2.9 million in Q1 2025, and down 20.29% quarter-over-quarter from $4.6 million in Q4 2025.
Nexalin Technology (NXL) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Nexalin Technology's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $3.7 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 27.4% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $20.0 million (up 43.58% YoY), while the FY2025 annual figure was $4.6 million, up 9.77% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $3.7 million, down from $4.6 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $8.4 million in Q3 2022, with the low at $1.6 million in Q2 2024.
- The 5-year median for Liabilities and Shareholders Equity is $4.6 million (2025), against an average of $4.8 million.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 886.09% in 2022, then tumbled 69.8% in 2024.
- Nexalin Technology's Liabilities and Shareholders Equity stood at $7.4 million in 2022, then sank by 51.13% to $3.6 million in 2023, then gained by 16.27% to $4.2 million in 2024, then rose by 9.77% to $4.6 million in 2025, then fell by 20.29% to $3.7 million in 2026.
- Business Quant data shows NXL's Liabilities and Shareholders Equity at $3.7 million in Q1 2026, $4.6 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Nexalin Technology | 7.01 Mn | 6.00 Mn | 8,897.00 | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.69 Mn |
| Dec 31, 2025 | 4.64 Mn |
| Sep 30, 2025 | 5.13 Mn |
| Jun 30, 2025 | 6.56 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 4.22 Mn |
| Sep 30, 2024 | 5.26 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | 3.63 Mn |
| Sep 30, 2023 | 4.43 Mn |
| Jun 30, 2023 | 5.18 Mn |
| Mar 31, 2023 | 5.93 Mn |
| Dec 31, 2022 | 7.43 Mn |
| Sep 30, 2022 | 8.35 Mn |
| Dec 31, 2021 | 753,698.00 |